Cortechs.ai | Reimbursement Essentials for Quantitative Imaging: Key Takeaways From Our Expert Webinar

Reimbursement Essentials for Quantitative Imaging: Key Takeaways From Our Expert Webinar

Quantitative imaging has rapidly become an integral component of clinical care—supporting earlier diagnosis, objective tracking, and improved confidence in interpretation. Our recent reimbursement webinar walked through best practices for billing, coding, and securing payment for NeuroQuant and OnQ Prostate, helping providers streamline claims and reduce payer friction. Below we review key takeaways for the webinar.  

Category III CPT Codes: The Foundation of Reimbursement 

For quantitative MRI post-processing, providers must bill the specific Category III CPT codes that describe the service performed: 

NeuroQuant® 

  • 0865T – Quantitative brain MRI analysis without same-day diagnostic MRI 
  • +0866T – Add-on code when completed with a same-day diagnostic MRI 

OnQ Prostate™ 

  • 0648T – Quantitative tissue analysis (single organ) without same-day diagnostic MRI 
  • +0649T – Add-on with same-day diagnostic MRI 

These codes are active, reimbursable, and payable across physician offices, IDTFs, freestanding imaging centers, and hospital outpatient departments. 

Coverage Landscape: Positive Momentum Across Payers 

Commercial Payers 

Many commercial insurers have now added Category III quantitative imaging codes to their covered services lists. The webinar highlighted a real-world example, which includes these codes for Commercial and Medicare Advantage plans.  

Medicare 

In the absence of a published policy, Medicare contractors can approve payment when services are “reasonable and necessary.”. Submitting claims helps establish local precedent and encourages future fee schedule assignment. 

Prior Authorization: When You Need It and What to Include 

Traditional Medicare generally does not require prior authorization. Commercial plans typically do. 

A strong prior auth request should include: 

  • Clear diagnosis and clinical history 
  • Rationale for quantitative analysis 
  • Relevant imaging reports and prior exams 
  • Peer-reviewed evidence supporting the indication 
  • Procedure description and site of service 

Documentation Tips to Strengthen Claims 

NeuroQuant 

Report should state: 

  • Automated volumetric analysis performed 
  • Comparison to normative data or prior scans 
  • Volumes or changes integrated into interpretation 

OnQ Prostate 

Report should reference: 

  • Quantitative RSI metrics 
  • Regions of interest and their values 
  • How quantitative output informed diagnostic impression 

Clear documentation improves reimbursement and audit readiness. 

Final Takeaway 

Reimbursement for quantitative imaging is achievable and increasingly common but requires the right coding, documentation, and workflow steps. With established APC payment, strong commercial adoption, and growing claim success, practices that follow the guidance reviewed in the webinar position themselves for reliable reimbursement moving forward. 

For personalized support, help navigating an appeal, or to get access to our reimbursement webinar, please contact: reimbursementsupport@cortechs.ai. 

More Resources

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

Scroll to Top